Chris Ryan

Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.

The FDA approved aminolevulinic acid hydrochloride plus PDT for the treatment of superficial basal cell carcinoma.

Gabriela Hobbs, MD, explains the importance of risk assessment and using disease factors to drive management approaches in myelofibrosis.

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.

Aaron Gerds, MD, outlines how cytopenias affect patients with myelofibrosis and how these can help drive JAK inhibitor selection.

The FDA approved ropeginterferon alfa-2b for the treatment of essential thrombocythemia.

The FDA approved rusfertide for the treatment of patients with polycythemia vera.

Sagar Lonial, MD, FACP, FASCO, shares the significance of the FDA approval of iberdomide/daratumumab/dexamethasone in replased/refractory multiple myeloma.

Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.

The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.

Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.

Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.

The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.

In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.

The FDA granted accelerated approval to RP1 plus nivolumab in anti–PD-1 therapy–pretreated advanced melanoma.

Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.

Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.

The FDA’s CTGTAC voted that the data from the IGNYTE trial are evaluable and clinically meaningful for RP1/nivolumab in advanced cutaneous melanoma.

The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.

Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.

An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.